Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.
- DOI
- 10.1136/rmdopen-2025-006670
- Published
- 2026 May 13
- Container
- RMD open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/rmdopen-2025-006670,
title = {Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.},
author = {Navarro-Compán V and Kiltz U and Mease PJ and Dubreuil M and Gaffney K and Deodhar A and de la Loge C and Prajapati C and Kavanagh S and Marzo-Ortega H},
year = {2026},
journal = {RMD open},
doi = {10.1136/rmdopen-2025-006670},
url = {https://doi.org/10.1136/rmdopen-2025-006670}
}RIS
TY - JOUR TI - Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. AU - Navarro-Compán V AU - Kiltz U AU - Mease PJ AU - Dubreuil M AU - Gaffney K AU - Deodhar A AU - de la Loge C AU - Prajapati C AU - Kavanagh S AU - Marzo-Ortega H PY - 2026 JO - RMD open DO - 10.1136/rmdopen-2025-006670 UR - https://doi.org/10.1136/rmdopen-2025-006670 ER -
APA
V, N., U, K., PJ, M., M, D., K, G., A, D., C, D. L. L., C, P., S, K., & H, M. (2026). Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.. RMD open. https://doi.org/10.1136/rmdopen-2025-006670